In parallel, ttAEs observed with BRAF and MEK inhibitors—including pyrexia, rash, arthralgia, photosensitivity, and laboratory abnormalities such as elevated liver enzymes—have also shown potential predictive implications. This evidence concerns the gene MAP2K7 and Fever.